LoongCrystal®PR Type Intraocular Lens Receives the First Approval through NMPA’s Innovative Device Approval Channel in 2025

LoongCrystal®PR Type intraocular lens (IOL), developed by Eyebright Medical, has been approved for marketing by the National Medical Products Administration (NMPA) on January 6, 2025.

The product is unique in its zero spherical aberration large optical zone and double concave stabilised arch height design, which can correct -3.25D to -18.00D myopia while significantly improving the quality of vision and providing wider peripheral vision. In addition, the use of patented Balacrylic™ balanced acrylic material ensures excellent mechanical properties and long-term stability, minimising post-operative arch height changes and refractive error. LoongCrystal®PR IOLs also offer a number of innovative advantages, including a slim volume to reduce the burden on the anterior chamber, a large optical zone of 6.0mm to reduce glare halos, and 10 models to finely match the morphology of different human eyes, providing a new option for personalised and refined ophthalmic surgery.

Disclaimer: The information on this platform is for informational purposes only and is based on publicly available sources, such as official press releases and regulatory databases. While we strive for accuracy, details may vary from the manufacturer’s official statements, particularly if they have been translated. We encourage readers to consult the manufacturer’s official website and communications for the most current and accurate information. This report is not a substitute for professional medical advice, diagnosis, or treatment and does not constitute an endorsement of any product or company. We do not accept responsibility for any errors, omissions, or actions taken based on the information provided.